Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

James Eric Cooper

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone7208480894

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Davis S, Wiebe C, Campbell K, Anobile C, Aubrey M, Stites E, Grafals M, Pomfret E, Nickerson P, Cooper JE. Adequate tacrolimus exposure modulates the impact of HLA class II molecular mismatch: a validation study in an American cohort. Am J Transplant. 2021 01; 21(1):322-328. PMID: 32888256.
      View in: PubMed
    2. Davis S, Gralla J, Klem P, Stites E, Wiseman A, Cooper JE. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies. Transplantation. 2020 04; 104(4):881-887. PMID: 32224815.
      View in: PubMed
    3. Cooper JE. Evaluation and Treatment of Acute Rejection in Kidney Allografts. Clin J Am Soc Nephrol. 2020 03 06; 15(3):430-438. PMID: 32066593.
      View in: PubMed
    4. Cooper JE. Desensitization in Kidney Transplant: A Risky (but Necessary?) Endeavor for Those With Limited Options. Transplantation. 2019 12; 103(12):2460-2461. PMID: 31343578.
      View in: PubMed
    5. Davis S, Gralla J, Klem P, Tong S, Wedermyer G, Freed B, Wiseman A, Cooper JE. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant. 2018 04; 18(4):907-915. PMID: 28925597.
      View in: PubMed
    6. Mithani Z, Gralla J, Adebiyi O, Klem P, Cooper JE, Wiseman AC. De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens. Exp Clin Transplant. 2018 02; 16(1):23-30. PMID: 28332959.
      View in: PubMed
    7. Davis S, Cooper JE. Acute antibody-mediated rejection in kidney transplant recipients. Transplant Rev (Orlando). 2017 01; 31(1):47-54. PMID: 28126347.
      View in: PubMed
    8. Weir MR, Burgess ED, Cooper JE, Fenves AZ, Goldsmith D, McKay D, Mehrotra A, Mitsnefes MM, Sica DA, Taler SJ. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol. 2015 Jun; 26(6):1248-60. PMID: 25653099.
      View in: PubMed
    9. Cooper JE, Gralla J, Klem P, Chan L, Wiseman AC. High dose intravenous immunoglobulin therapy for donor-specific antibodies in kidney transplant recipients with acute and chronic graft dysfunction. Transplantation. 2014 Jun 27; 97(12):1253-9. PMID: 24937199.
      View in: PubMed
    10. Gralla J, Le CN, Cooper JE, Wiseman AC. The risk of acute rejection and the influence of induction agents in lower-risk African American kidney transplant recipients receiving modern immunosuppression. Clin Transplant. 2014 Mar; 28(3):292-8. PMID: 24476453.
      View in: PubMed
    11. Alfonso J, Gralla J, Klem P, Chan L, Wiseman AC, Cooper JE. High-Dose Intravenous Immunoglobulin Therapy for Donor Specific Antibodies in Kidney Transplant Recipients with Acute and Chronic Graft Dysfunction: Updates on Previously Reported Cohorts. Clin Transpl. 2014; 161-70. PMID: 26281141.
      View in: PubMed
    12. Cooper JE, Wiseman AC. Acute kidney injury in kidney transplantation. Curr Opin Nephrol Hypertens. 2013 Nov; 22(6):698-703. PMID: 24076557.
      View in: PubMed
    13. Renner B, Klawitter J, Goldberg R, McCullough JW, Ferreira VP, Cooper JE, Christians U, Thurman JM. Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol. 2013 Nov; 24(11):1849-62. PMID: 24092930.
      View in: PubMed
    14. Cooper JE, Gralla J, Adebiyi O, Wiseman AC, Chan L. Donor specific antibodies before and after kidney transplant: the University of Colorado Experience. Clin Transpl. 2013; 407-12. PMID: 25095536.
      View in: PubMed
    15. Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC. Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation. 2011 May 27; 91(10):1103-9. PMID: 21403588.
      View in: PubMed
    16. Cooper JE, Gralla J, Chan L, Wiseman AC. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Clin Transpl. 2011; 359-64. PMID: 22755431.
      View in: PubMed
    17. Cooper JE, Huskey J, Chan L, Wiseman AC. Preemptive retransplant for BK virus nephropathy without concurrent transplant nephrectomy. Transplantation. 2010 Aug 15; 90(3):331-2. PMID: 20683427.
      View in: PubMed
    18. Cooper JE, Wiseman AC, Chan L. Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases. Clin Transpl. 2010; 415-20. PMID: 21698838.
      View in: PubMed
    19. Klem P, Cooper JE, Weiss AS, Gralla J, Owen P, Chan L, Wiseman AC. Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients. Transplantation. 2009 Oct 15; 88(7):891-6. PMID: 19935460.
      View in: PubMed
    20. Cooper JE, Wiseman AC, Chan L. Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases. Clin Transpl. 2009; 455-9. PMID: 20524314.
      View in: PubMed
    Cooper's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (114) concept(s)
    _
    Co-Authors Expand Description
    See all (10) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)